ESMO 2018: Cabozantinib is effective in advanced RCC regardless of PD-L1 expression
An analysis of the data from the CABOSUN and METEOR [...]
An analysis of the data from the CABOSUN and METEOR [...]
We are very disappointed by the Scottish Medicines Consortium's (SMC) [...]
The National Institute for Health and Care Excellence (NICE) has published final [...]
Today, the National Institute for Health and Care Excellence (NICE) have recommended [...]
A recent meta-analysis evaluating the efficacy of first- and second-line [...]
The National Institute for Health and Care Excellence (NICE) have issued an [...]
The European Commission has approved cabozantinib (Cabometyx) for the first-line [...]
Cabozantinib significantly improves overall survival in previously treated patients with [...]
The glutaminase inhibitor, CB-839 has been granted Fast Track designation [...]
Calithera Biosciences announced earlier this week that the US Food [...]